AAV2-mediated striatum delivery of human CDNF prevents the deterioration of midbrain dopamine neurons in a 6-hydroxydopamine induced parkinsonian rat model

Experimental Neurology

Volumn 248, Issue , 2013, Pages 148-156

  Ren, Xinmiao ^a   Zhang, Ting ^a   Gong, Xiaoli ^a   Hu, Guanzheng ^a   Ding, Wei ^a   Wang, Xiaomin ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

6 OHDA; AAV; CDNF; Parkinson's disease; PET

Indexed keywords

CEREBRAL DOPAMINE NEUROTROPHIC FACTOR; NEUROTROPHIC FACTOR; OXIDOPAMINE; PARVOVIRUS VECTOR; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ADENO ASSOCIATED VIRUS; ADENO ASSOCIATED VIRUS TYPE 2; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; CELL FUNCTION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DRUG EFFECT; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; MALE; MESENCEPHALON; NERVE CELL LESION; NERVE FIBER; NEUROPROTECTION; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA PARS COMPACTA; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

6-OHDA; AAV; CDNF; PARKINSON'S DISEASE; PET;

ANIMALS; DEPENDOVIRUS; DOPAMINERGIC NEURONS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; LOCOMOTION; MALE; MESENCEPHALON; MOTOR ACTIVITY; NERVE GROWTH FACTORS; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84880006379     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2013.06.002     Document Type: Article

References (44)

1. Aoi M., Date I., Tomita S., Ohmoto T. Single administration of GDNF into the striatum induced protection and repair of the nigrostriatal dopaminergic system in the intrastriatal 6-hydroxydopamine injection model of hemiparkinsonism. Restor. Neurol. Neurosci. 2001, 17:31-38.
2. Back S., Peranen J., Galli E., Pulkkila P., Lonka-Nevalaita L., Tamminen T., Voutilainen M.H., Raasmaja A., Saarma M., Mannisto P.T., Tuominen R.K. Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson's disease. Brain Behav. 2013, 3:75-88.
3. Bankiewicz K.S., Forsayeth J., Eberling J.L., Sanchez-Pernaute R., Pivirotto P., Bringas J., Herscovitch P., Carson R.E., Eckelman W., Reutter B., Cunningham J. Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol. Ther. 2006, 14:564-570.
4. Brizard M., Carcenac C., Bemelmans A.P., Feuerstein C., Mallet J., Savasta M. Functional reinnervation from remaining DA terminals induced by GDNF lentivirus in a rat model of early Parkinson's disease. Neurobiol. Dis. 2006, 21:90-101.
5. Brooks D.J. Morphological and functional imaging studies on the diagnosis and progression of Parkinson's disease. J. Neurol. 2000, 247(Suppl. 2):II11-II18.
6. Brownell A.L., Elmaleh D.R., Meltzer P.C., Shoup T.M., Brownell G.L., Fischman A.J., Madras B.K. Cocaine congeners as PET imaging probes for dopamine terminals. J. Nucl. Med. 1996, 37:1186-1192.
7. Burke R.E. Alpha-synuclein and Parkinson's disease. Brain Res. Bull. 1999, 50:465-466.
8. Burton E.A., Glorioso J.C., Fink D.J. Gene therapy progress and prospects: Parkinson's disease. Gene Ther. 2003, 10:1721-1727.
9. Cicchetti F., Brownell A.L., Williams K., Chen Y.I., Livni E., Isacson O. Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur. J. Neurosci. 2002, 15:991-998.
10. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
11. Farrer M.J. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat. Rev. Genet. 2006, 7:306-318.
12. Georgievska B., Kirik D., Bjorklund A. Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer. Exp. Neurol. 2002, 177:461-474.
13. Hadlock G.C., Nelson C.C., Baucum A.J., Hanson G.R., Fleckenstein A.E. Ex vivo identification of protein-protein interactions involving the dopamine transporter. J. Neurosci. Methods 2011, 196:303-307.
14. Hoffer B.J. Commentary on chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease. Merja H. Voutilainen et al. Exp. Neurol. 2011, 230:162-166.
15. Lang A.E., Gill S., Patel N.K., Lozano A., Nutt J.G., Penn R., Brooks D.J., Hotton G., Moro E., Heywood P., Brodsky M.A., Burchiel K., Kelly P., Dalvi A., Scott B., Stacy M., Turner D., Wooten V.G., Elias W.J., Laws E.R., Dhawan V., Stoessl A.J., Matcham J., Coffey R.J., Traub M. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol. 2006, 59:459-466.
16. Lee C.S., Samii A., Sossi V., Ruth T.J., Schulzer M., Holden J.E., Wudel J., Pal P.K., de la Fuente-Fernandez R., Calne D.B., Stoessl A.J. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann. Neurol. 2000, 47:493-503.
17. Lindholm P., Saarma M. Novel CDNF/MANF family of neurotrophic factors. Dev. Neurobiol. 2010, 70:360-371.
18. Lindholm P., Voutilainen M.H., Lauren J., Peranen J., Leppanen V.M., Andressoo J.O., Lindahl M., Janhunen S., Kalkkinen N., Timmusk T., Tuominen R.K., Saarma M. Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature 2007, 448:73-77.
19. Liu L., Wang Y., Li B., Jia J., Sun Z., Zhang J., Tian J., Wang X. Evaluation of nigrostriatal damage and its change over weeks in a rat model of Parkinson's disease: small animal positron emission tomography studies with [(11)C]beta-CFT. Nucl. Med. Biol. 2009, 36:941-947.
20. Lu Y. Recombinant adeno-associated virus as delivery vector for gene therapy-a review. Stem Cells Dev. 2004, 13:133-145.
21. Marks W.J., Ostrem J.L., Verhagen L., Starr P.A., Larson P.S., Bakay R.A., Taylor R., Cahn-Weiner D.A., Stoessl A.J., Olanow C.W., Bartus R.T. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol. 2008, 7:400-408.
22. Meltzer P.C., Liang A.Y., Brownell A.L., Elmaleh D.R., Madras B.K. Substituted 3-phenyltropane analogs of cocaine: synthesis, inhibition of binding at cocaine recognition sites, and positron emission tomography imaging. J. Med. Chem. 1993, 36:855-862.
23. Mochizuki H., Mizuno Y. Gene therapy for Parkinson's disease. J. Neural Transm. Suppl. 2003, 205-213.
24. Nagahara A.H., Tuszynski M.H. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat. Rev. Drug Discov. 2011, 10:209-219.
25. Nirenberg M.J., Vaughan R.A., Uhl G.R., Kuhar M.J., Pickel V.M. The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. J. Neurosci. 1996, 16:436-447.
26. 18F]CFT. Ann. Neurol. 2000, 47:804-808.
27. Oiwa Y., Yoshimura R., Nakai K., Itakura T. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease. Brain Res. 2002, 947:271-283.
28. Parkash V., Lindholm P., Peranen J., Kalkkinen N., Oksanen E., Saarma M., Leppanen V.M., Goldman A. The structure of the conserved neurotrophic factors MANF and CDNF explains why they are bifunctional. Protein Eng. Des. Sel. 2009, 22:233-241.
29. Peterson A.L., Nutt J.G. Treatment of Parkinson's disease with trophic factors. Neurotherapeutics 2008, 5:270-280.
30. Petrova P., Raibekas A., Pevsner J., Vigo N., Anafi M., Moore M.K., Peaire A.E., Shridhar V., Smith D.I., Kelly J., Durocher Y., Commissiong J.W. MANF: a new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons. J. Mol. Neurosci. 2003, 20:173-188.
31. Rosenblad C., Kirik D., Devaux B., Moffat B., Phillips H.S., Bjorklund A. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle. Eur. J. Neurosci. 1999, 11:1554-1566.
32. Rosenblad C., Kirik D., Bjorklund A. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model. Exp. Neurol. 2000, 161:503-516.
33. Rosenblad C., Georgievska B., Kirik D. Long-term striatal overexpression of GDNF selectively downregulates tyrosine hydroxylase in the intact nigrostriatal dopamine system. Eur. J. Neurosci. 2003, 17:260-270.
34. Sajadi A., Bauer M., Thony B., Aebischer P. Long-term glial cell line-derived neurotrophic factor overexpression in the intact nigrostriatal system in rats leads to a decrease of dopamine and increase of tetrahydrobiopterin production. J. Neurochem. 2005, 93:1482-1486.
35. Sauer H., Oertel W.H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 1994, 59:401-415.
36. Schober A. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res. 2004, 318:215-224.
37. Shih M.C., Hoexter M.Q., Andrade L.A., Bressan R.A. Parkinson's disease and dopamine transporter neuroimaging: a critical review. Sao Paulo Med. J. 2006, 124:168-175.
38. Sossi V., de la Fuente-Fernandez R., Schulzer M., Troiano A.R., Ruth T.J., Stoessl A.J. Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study. Ann. Neurol. 2007, 62:468-474.
39. 11C-methylphenidate PET. J. Nucl. Med. 2012, 53:813-822.
40. Stoessl A.J. Positron emission tomography in premotor Parkinson's disease. Parkinsonism Relat. Disord. 2007, 13(Suppl. 3):S421-S424.
41. Voutilainen M.H., Back S., Porsti E., Toppinen L., Lindgren L., Lindholm P., Peranen J., Saarma M., Tuominen R.K. Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of Parkinson's disease. J. Neurosci. 2009, 29:9651-9659.
42. Voutilainen M.H., Back S., Peranen J., Lindholm P., Raasmaja A., Mannisto P.T., Saarma M., Tuominen R.K. Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease. Exp. Neurol. 2011, 228:99-108.
43. Yan Z., Lei-Butters D.C., Zhang Y., Zak R., Engelhardt J.F. Hybrid adeno-associated virus bearing nonhomologous inverted terminal repeats enhances dual-vector reconstruction of minigenes in vivo. Hum. Gene Ther. 2007, 18:81-87.
44. Yuan H., Sarre S., Ebinger G., Michotte Y. Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease. J. Neurosci. Methods 2005, 144:35-45.